Duality Biotherapeutics, Inc. reported no changes in its authorized or issued share capital for the month ended 28 February 2026. Authorized share capital remained at 200,000,000 ordinary shares, each with a par value of USD 0.0001, for a total of USD 20,000. The total issued shares stood at 90,137,714, with no treasury shares.

The company confirmed its public float exceeded the applicable 25% requirement. Under the Pre-IPO Equity Incentive Plan, 19,101,570 share options remained outstanding, and 13,745,025 shares were issuable or transferable upon their exercise. No new share issuances or treasury share transactions took place under any other agreements or share schemes during the month.